The ecog performance status determines ability of patient to tolerate therapies in serious illness, specifically for chemotherapy, simpler than the karnofsky. Antioquia, 2003 abstract the objective of this paper is describe the process of. Valoracion general del paciente oncologico avanzado. Programs may use ppsv2 with appropriate recognition. The revised international prognostic index ripi for diffuse large bcell lymphoma predicts overall and progression free survival based on risk factors. We would like to show you a description here but the site wont allow us. These scales and criteria are used by doctors and researchers to assess how a patients disease is progressing, assess how the. It is the dedication of healthcare workers that will lead us through this crisis. In this study, 101 patients attending a rapid access clinic at papworth hospital with a diagnosis of lung cancer were asked to assess their own ecog ps score on a scale between 0 and 4. To increase the internal consistency we suggest to separate the options of each item to improve. The use of nitrogen mustards in the palliative treatment of carcinom. Oken mm, creech rh, tormey dc, horto j, davis te, mcfadden et, carbone pp.
Moving beyond karnofsky and ecog performance status. The palliative performance scale version 2 ppsv2 tool is to victoria hospice society and replaces the first pps published in 1996 j pall care 94. In 1960, ecog introduced the ecog ps scale with only six points, ranging from 0. Toxicity and response criteria of the eastern cooperative oncology group. How teachers and students can make the quick transition to online learning. It cannot be altered or used in any way other than as intended and described here. Eastern cooperative oncology group ecog performance status. International prognostic index for diffuse large bcell. Patients with poor performance status ecog 4 showed significantly higher nose scores t student 3. Due to their subjective nature, both ecog ps and kps scales have been criticized for. Moving beyond karnofsky and ecog performance status assessments with new technologies. The scale was developed by the eastern cooperative oncology group ecog, now part of the ecogacrin cancer research group, and published in 1982. Charlson comorbidity index predicts the tenyear mortality for a patient who may have a range of comorbid conditions.
623 932 8 1230 378 1304 512 139 1534 1348 1184 174 1343 643 157 1394 444 1082 948 56 535 400 482 1060 284 1232 627 31 1191 744 299 1082